Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 97,070,008
  • Shares Outstanding, K 1,085,430
  • Annual Sales, $ 22,871 M
  • Annual Income, $ -204,100 K
  • 36-Month Beta 0.25
  • Price/Sales 4.24
  • Price/Cash Flow 16.15
  • Price/Book 6.65

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.64 +4.53%
on 06/27/18
90.13 -1.84%
on 07/18/18
+2.19 (+2.54%)
since 06/20/18
3-Month
77.09 +14.76%
on 05/04/18
90.13 -1.84%
on 07/18/18
+9.41 (+11.90%)
since 04/20/18
52-Week
73.69 +20.06%
on 02/09/18
90.13 -1.84%
on 07/18/18
+3.72 (+4.39%)
since 07/20/17

Most Recent Stories

More News
Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label

Lilly (LLY) updates Trulicity's label to include data from a new study on patients with type II diabetes suffering from moderate to severe chronic kidney disease.

GHDX : 57.34 (-1.66%)
NVO : 50.44 (+1.26%)
LLY : 88.47 (-1.07%)
VNDA : 20.80 (-0.72%)
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.

JNJ : 125.85 (-0.07%)
MRK : 62.52 (+0.02%)
LLY : 88.47 (-1.07%)
NVS : 82.27 (+1.82%)
ABBV : 88.91 (-1.16%)
RHHBY : 29.4700 (+1.94%)
PFE : 37.33 (-0.08%)
LLY vs. NVO: Which Stock Is the Better Value Option?

LLY vs. NVO: Which Stock Is the Better Value Option?

NVO : 50.44 (+1.26%)
LLY : 88.47 (-1.07%)
LLY vs. NVO: Which Stock Is the Better Value Option?

LLY vs. NVO: Which Stock Is the Better Value Option?

NVO : 50.44 (+1.26%)
LLY : 88.47 (-1.07%)
Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

LLY : 88.47 (-1.07%)
INCY : 69.20 (-1.30%)
ABBV : 88.91 (-1.16%)
AMGN : 190.49 (-0.66%)
Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study

Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.

LLY : 88.47 (-1.07%)
TEVA : 22.93 (-0.56%)
REGN : 367.11 (-0.17%)
PFE : 37.33 (-0.08%)
Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint

CARMELINA® (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence...

LLY : 88.47 (-1.07%)
The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon

The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon

NFLX : 361.05 (-0.87%)
TJX : 97.07 (-0.63%)
LLY : 88.47 (-1.07%)
BK : 52.46 (-0.51%)
RTN : 201.44 (+0.03%)
Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon

Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon

NFLX : 361.05 (-0.87%)
TJX : 97.07 (-0.63%)
SYK : 174.30 (+0.83%)
LLY : 88.47 (-1.07%)
BK : 52.46 (-0.51%)
RTN : 201.44 (+0.03%)
J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay

The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.

GHDX : 57.34 (-1.66%)
JNJ : 125.85 (-0.07%)
LLY : 88.47 (-1.07%)
VNDA : 20.80 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade LLY with:

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 89.81
1st Resistance Point 89.14
Last Price 88.47
1st Support Level 88.03
2nd Support Level 87.59

See More

52-Week High 90.13
Last Price 88.47
Fibonacci 61.8% 83.85
Fibonacci 50% 81.91
Fibonacci 38.2% 79.97
52-Week Low 73.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar